Treatment of hypertension: mono-therapy versus [Zofenopril and Hydrochlorothiazide] combined therapy: A review

Francesco Crespi*
Department of Biology, Neurosciences CEDD GlaxoSmithKline, Medicines Research Centre, Italy

Abstract
The need of at least two antihypertensive drugs to achieve optimal blood pressure (BP) control in patients with hypertension appears more and more evident. In particular, the combination of the angiotensin-converting enzyme inhibitor zofenopril together with hydrochlorothiazide (diuretic) at the dose 30/12.5 mg/day respectively is now approved in Italy, France, Switzerland and Greece for the treatment of mild to moderate hypertension.

The aim of this work is therefore to collect results from all available reports in order to analyse efficacy, safety and metabolic effects of such combined therapy versus Zofenopril alone. Efficacy and safety data were therefore assessed taking into account the number of subjects (weighted analysis).

It emerges that in various clinical trials the combined therapy was significantly more effective in treating hypertension when comparing to mono-therapy with the further advantage of a safety profile. Therefore the combined therapy analysed here appears to be a positive improvement of the currently available therapy for patients with BP.

Introduction
Angiotensin-converting enzyme inhibitors (ACEIs) interfere with the renin-angiotensin system and have beneficial actions when used in a range of cardiovascular disorders. Over the years, following preclinical evidences, several second- and third-generation ACEIs have been introduced into the clinic. In particular, preclinical and clinical findings have established Zofenopril (Z) as a potent sulphhydril ACE inhibitor, characterized by high lipophilicity, high potency, significant tissue selectivity, antioxidant and tissue protective activities and a long duration of action.

Efficacy as well as tolerability is major quality of an antihypertensive drug while the adverse effects associated with treatment are among the most common causes of poor compliance with antihypertensive treatment [1,2]. Therefore, antihypertensive drugs combined with a better tolerability profile can aid compliance and help better the hypertensive population to benefit from experiences in dedicated clinical studies [3]. Indeed, one of the major purposes of Research is not only developing drugs with new mechanisms of action, but also improving already existing drugs with either more effectiveness and/ or fewer adverse effects.

For instance, the combination of an ACE inhibitor and a diuretic presents three distinct advantages:

- Reduced probability of adverse metabolic effects often associated with the use of high-dose diuretic therapy only;
- Reduced tendency of thiazide diuretics to lower serum potassium levels;
- Z has a direct antioxidant effect in humans [4] and therefore may counteract the putative increase of oxidant activity via an activation of the rennin-angiotensin system due to the diuretic hydrochlorothiazide (HCTZ) [5,6].

Further advantages are

I. The fixed combination Z+HCTZ diminish the amount of tablets per day, thus improving patient compliance.

II. Combination therapy may be superior or, at least, as equally effective as mono-therapy in the prevention of organ damage associated with hypertension. In particular, it has been shown that ACE inhibitor therapy in combination with a diuretic can reduce left ventricular hypertrophy (LVH) [5] and can help in retarding the progression of renal failure in diabetic and other types of nephropathy [7–9].

The objective of this paper is therefore to further assess the comparative efficacy and tolerability of Z alone versus Z in combination with HCTZ. The feasibility of evaluation of glucose, urine protein and lipid profile during treatment is also considered when available.

Methods
Efficacy and tolerability data have been obtained from the studies included in this meta-analysis that were identified through...
bibliographic searches in computerised databases [i.e. PubMed] using the terms ‘Z’ and ‘clinical trial’ as well as from unpublished reports. In particular, two double blind parallel studies have presented data from patients treated with only Z (n=18 or n= 19, respectively) or only HCTZ (n=19 each) at doses 30 mg/day n=12 or 60 mg/day n=6 [10] or doses 25 mg/day n=10 or 50 mg/day n=9 [11], respectively.

Malacco and Omboni also in a double blind parallel study, displayed data from 89 patients treated with only Z (30 mg/day) or 167 with Z + HCTZ (30 + 12.5 mg/day) [12].

Parati, et al. again in a double blind parallel study displayed data from 106 patients treated with various doses of Z (15, or 30, or 60 mg/day, n=36, 36, or 34, respectively) or 71 patients with two doses of HCTZ (12.5, or 25mg/day; n=36, or 35, respectively) or 172 patients treated with Z+HCTZ (Z: dose:15 mg/day; n=70; 30 mg/day; n=69; 60 mg/day: n=33; HCTZ dose:12.5 mg/day: n=101; 25mg/day: n=71) [13].

Mäkel [14,15] are two open PMSs (unpublished) to evaluate the efficacy, tolerability and safety of Z during treatment of hypertension [14] or during treatment in diabetic patients [15]. In both pMSs data are from patients treated with only Z or with Z+HCTZ at various doses as follow:

- 1042 patients treated with Z alone: 7.5 mg/day: n=11; 15 mg/day: n=331; 30 mg/day: n=666; 45 mg/day: n=9; 60 mg/day: n=25;
- 261 patients treated with Z + HCTZ [i.e. Z: 7.5 mg/day: n=3; 15 mg/day: n=64; 30 mg/day: n=181; 60 mg/day: n=13 + constant dosage of HCTZ i.e. 12.5 mg/day: n=261] [14].
- 446 patients treated with Z alone: 7.5 mg/day: n=1; 15 mg/day: n=191; 30 mg/day: n=240; 45 mg/day: n=2; 60 mg/day: n=12.
- 108 patients treated with Z+HCTZ [i.e. Z: 7.5 mg/day: n=1; 15 mg/day: n=42; 30 mg/day: n=61; 60 mg/day: n=4 + constant dosage of HCTZ i.e.12.5 mg/day: n=108] [15].

Malacco, et al. described a multicenter (58 centers), randomized, double blind parallel-group study. Briefly, a 4-week placebo washout period, during which previous antihypertensive treatment had to be withdrawn, was followed by 12 weeks of randomized treatment with Z + HCTZ (30 + 12.5mg/day) or monotherapy with Z alone 30 mg, respectively. Patients were randomized in a ratio of 2:1. Randomization was done by blocks and generated by a computer. The final per protocol population for this post hoc analysis comprised 246 patients (n=157 Z + HCTZ and n= 89 Z mono-therapy) [16].

Results

The results are taking into account only the real number of subjects effectively taking part in each study. For instance, since the patients in references [10] and [11] seem to be the same subject’s data have been therefore included in the analysis once. All data were normalized to mmol/L ± Standard Deviation.

The data from subjects treated with Z alone, HCTZ alone or Z + HCTZ have been analysed as distinct groups (Table 1).

Statistical comparison of systolic and diastolic blood pressure: Only the above six studies [i.e., ref # 10-16] include comparisons between Z alone and the combined therapy Z + HCTZ and are then used for statistics [Student t test].

In all these studies, the antihypertensive effect of Z alone as well as that of combined therapy Z + HCTZ is statistically significant [p < 0.05] versus pre-treatment values of both systolic and diastolic blood pressure [SBP and DBP, respectively]. Furthermore, the contribution of HCTZ to the anti-hypertensive effect of Z is statistically significant [p < 0.05] for both SBP and DBP with exception for SBP in reference [14] (Figure 1).

Response rates and Mantel-Haenszel odd ratios: Response was defined as having a reduction of 10 mmHg or more of the diastolic blood pressure or having a diastolic blood pressure not higher than 90 mmHg.

Response rates or individual data were available only in three studies [13-15] and could be therefore analysed. In each one of these studies as well as and on the whole the odd ratio is significantly greater than 1.00, thus HCTZ is significantly strengthening the antihypertensive effect of Z alone (Table 2 and Figure 2).

In the post hoc analysis described in study [16] 246 patients [139 men, 107 women; aged 54 ± 11 S.D. years] were treated, and precisely n=89 with Z monotherapy or n=157 with the combined therapy Z + HCTZ. These two groups were selected with very similar characteristics of age as well as clinical features as shown in figures 3 and 4. Indeed, no significant between-group differences were found before treatments.

Initial clinical traits (mean ± S.D.) of the two groups of patients that will be successively treated with either Z + HCTZ or with Z alone. At the end of the 12 weeks of double-blind daily treatment with Z + HCTZ (30 mg + 12.5 mg) or with Z alone (30 mg) the reduction

<table>
<thead>
<tr>
<th>Ref. #</th>
<th>n</th>
<th>Age</th>
<th>S.D.</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>38</td>
<td>54.5</td>
<td>9.5</td>
<td>16/22</td>
</tr>
<tr>
<td>12</td>
<td>256</td>
<td>52</td>
<td>12.3</td>
<td>150/100</td>
</tr>
<tr>
<td>13</td>
<td>349</td>
<td>56.6</td>
<td>11.8</td>
<td>198/151</td>
</tr>
<tr>
<td>14</td>
<td>1303</td>
<td>61.7</td>
<td>12.7</td>
<td>609/673</td>
</tr>
<tr>
<td>15</td>
<td>554</td>
<td>64.7</td>
<td>12.1</td>
<td>281/269</td>
</tr>
<tr>
<td>16</td>
<td>246</td>
<td>54</td>
<td>11</td>
<td>139/107</td>
</tr>
<tr>
<td>Total</td>
<td>2746</td>
<td>55.9</td>
<td>11.4</td>
<td>1393/1328*</td>
</tr>
</tbody>
</table>

Figure 1. Statistical comparison of systolic and diastolic blood pressure.

### Table 1. The data from subjects treated with Z alone, HCTZ alone or Z + HCTZ have been analysed as distinct groups. *(In 25 cases in the studies [14] and [15] the gender was not recorded)*

<table>
<thead>
<tr>
<th>Ref. #</th>
<th>n</th>
<th>Age</th>
<th>S.D.</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>38</td>
<td>54.5</td>
<td>9.5</td>
<td>16/22</td>
</tr>
<tr>
<td>12</td>
<td>256</td>
<td>52</td>
<td>12.3</td>
<td>150/100</td>
</tr>
<tr>
<td>13</td>
<td>349</td>
<td>56.6</td>
<td>11.8</td>
<td>198/151</td>
</tr>
<tr>
<td>14</td>
<td>1303</td>
<td>61.7</td>
<td>12.7</td>
<td>609/673</td>
</tr>
<tr>
<td>15</td>
<td>554</td>
<td>64.7</td>
<td>12.1</td>
<td>281/269</td>
</tr>
<tr>
<td>16</td>
<td>246</td>
<td>54</td>
<td>11</td>
<td>139/107</td>
</tr>
<tr>
<td>Total</td>
<td>2746</td>
<td>55.9</td>
<td>11.4</td>
<td>1393/1328*</td>
</tr>
</tbody>
</table>

Figure 1. Statistical comparison of systolic and diastolic blood pressure.

### Table 2. Response rates and Mantel-Haenszel odd ratios.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Z</th>
<th>Z+HCTZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>886</td>
<td>505</td>
</tr>
<tr>
<td>%</td>
<td>76.3</td>
<td>82.8</td>
</tr>
<tr>
<td>Odd Ratio</td>
<td>lower limit</td>
<td>upper limit</td>
</tr>
<tr>
<td>95%</td>
<td>95%</td>
<td></td>
</tr>
<tr>
<td>1.493</td>
<td>1.163</td>
<td>1.917</td>
</tr>
</tbody>
</table>
of the cardiovascular risk appeared significantly (p < 0.01) greater in the combined therapy group than in the monotherapy group: i.e. 1.9% versus 0.2%, respectively. Actually, this study did classified patients in quartiles of cardiovascular risk level (risk of developing a cardiovascular disease in the next 10 years; quartile 1 = lowest risk, to quartile 4 = highest risk) accordingly to the SCORE Project depicted by Conroy et al., [45].

It appeared that the combined therapy Z + HCTZ was followed by significant (p < 0.01) reduction in 10-year risk of cardiovascular disease in patients of the higher-risk quartile. More precisely, 22 out of the 44 patients at high cardiovascular risk had their risk reduced to a lower level after 12 weeks of treatment.

Decreased levels (mean ± S.D.) of sitting systolic BP (SBP) or office diastolic blood pressure (DBP) as following 12 weeks of treatment, by quartiles (Q) of cardiovascular risk level (quartile 1 = lowest risk to quartile 4 = highest risk), in patients (approximately n = 60 each Q) treated with Z + HCTZ (n = 157) or Z alone.

Statistical significance of the trend of the difference between combined versus mono-therapy over the 4 quartiles was determined by analysis of variance and resulted in a trend p < 0.01 (Table 3).

**Table 3.** Decreased levels (mean ± S.D.) of sitting systolic BP (SBP) or office diastolic blood pressure (DBP).

<table>
<thead>
<tr>
<th></th>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP decrease</td>
<td>18 ± 12</td>
<td>22 ± 17</td>
<td>21 ± 13</td>
<td>24 ± 13</td>
</tr>
<tr>
<td>Z alone</td>
<td>8 ± 16</td>
<td>13 ± 15</td>
<td>17 ± 13</td>
<td>17 ± 17</td>
</tr>
<tr>
<td>DBP decrease</td>
<td>14 ± 6</td>
<td>14 ± 9</td>
<td>14 ± 9</td>
<td>15 ± 8</td>
</tr>
<tr>
<td>Z alone</td>
<td>9 ± 8</td>
<td>11 ± 11</td>
<td>11 ± 9</td>
<td>11 ± 7</td>
</tr>
</tbody>
</table>
(i) an improved patient compliance while minimising BP variability; (ii) a greater protection against major cardiovascular events and development of target end-organ damage.

In order to treat hypertension with associated risk factors, international guidelines [22,23] propose the use of angiotensin-converting enzyme (ACE) inhibitors, possibly in combination with other antihypertensive drugs, because of their protective effects at cardio, renal and vascular level.

Z is a sulphydryl ACE inhibitor highly lipophilic and with tissue-protective properties [4,24-26]. Since its selective, long-acting ACE inhibitory activity, it appears beneficial and well tolerated for the treatment of a number of cardiovascular diseases (eg., acute myocardial infarction, [27-29] heart failure, [30,31] and essential hypertension [32-34].

In high-risk hypertensive patients, adequate blood pressure (BP) control is difficult to achieve with a single antihypertensive drug [22,23,35]. This is the reason various studies have tested the combination of ACE inhibitors with other antihypertensive drugs. In particular, it has been shown that the combination of low-dose HCTZ (12.5 mg) with Z 30 mg results in an additional 4 to 8 mmHg antihypertensive effect with favourable tolerability [13,36] and that this combination therapy might be particularly useful in high-risk patients, such as those with metabolic syndrome [37].

**Clinical efficacy**

Z is characterised by long-lasting tissue penetration and sustained cardiac ACE inhibition [38] and three key clinical studies demonstrated that the combination of Z+HCTZ 30/12.5 mg/day was more effective in maintaining BP reductions than either agent administered as mono-therapy [13,39]. Accordingly, such fixed-dose combination is approved in Italy, France, Switzerland and Greece for the management of mild to moderate hypertension. In particular, the **first of the three studies** were a 12-week, multi-centre, dose-response analysis in 353 patients aged 18–75 years with essential hypertension, where the combined therapy Z + HCTZ (30/12.5 or 60/12.5 mg/day) appeared to be more effective in maintaining continuous 24-hour BP control (i.e. seated DBP <90 mm Hg), than both compounds used as mono-therapy [13]. The **second of the three studies** is a 36-week comparison of Z + HCTZ versus zofenopril mono-therapy. It resulted in a significantly [p < 0.01] greater efficacy of Z + HCTZ combination therapy in decreasing BP in 463 patients aged 18–75 years with mild to moderate hypertension. Briefly, they presented after treatment a SBP < 140 mmHg following a DBP reduction ≥ 20 mmHg and a DBP < 90 mmHg because of a DBP reduction ≥ 10 mmHg (Table 3). The **third of the three studies** involved 369 patients, 18–70 years of age with mild to moderate hypertension. In fact, the patients of the third study were the “non-responders” to the mono-therapy in study 2 as they were successively randomised to double-blind treatment for a further 8 weeks with either Z alone 30 mg/day or with the combined therapy Z + HCTZ 30/12.5 mg/day. It appeared that the mono-therapy again did not reduce significantly SBP and/or DBP. In contrast, the combination Z + HCTZ was able to significantly reduce SBP and DBP as shown in table 3. Briefly, it appeared that BP reached a plateau at week 8 in patients receiving the combined therapy.

463 patients with mild to moderate hypertension [36,39] submitted to mono or combined therapy [parallel group comparative study] for 4 weeks and 369 non responders successively submitted to mono or combined therapy [Non responder study: 8 weeks] (Table 4).

**Safety and tolerability**

The clinical trials studying the combination Z + HCTZ versus Z or HCTZ mono-therapy and involving about 600 patients reported that dizziness, headache cough [and polyuria] are the predominant adverse events in the combined as well as in the mono-therapy. They are mild to moderate in severity and not linked with age or sex [13,39,40]. Thus it is concluded that the combined Z + HCTZ therapy results in adverse events as expected with ACE-inhibitor therapy.

In the dose-response study, a total of 9.9% of patients reported an adverse event, with a majority (64.3%) of mild intensity [13]. Again in such study the tolerability of 30/12.5 mg/day was better than that of 60/12.5 mg/day and treatment withdrawal occurred in only 1.7% of patients. There were no changes in low-density lipoprotein cholesterol, triglycerides, blood glucose or uric acid levels with combination therapy in the dose-response study, a total of 9.9% of patients reported an adverse event, with a majority (64.3%) of mild intensity [13]. Again in such study the tolerability of 30/12.5 mg/day was better than that of 60/12.5 mg/day and treatment withdrawal occurred in only 1.7% of patients. There were no changes in low-density lipoprotein cholesterol, triglycerides, blood glucose or uric acid levels with combination therapy that also showed no negative effect on heart rate [39]. In addition, in the parallel-group comparative study, the proportions of patients discontinuing treatment because of adverse events were 11% in the Z mono-therapy while they were 6% only in the Z + HCTZ combined therapy. Furthermore, no single adverse event resulted in discontinuation for more than 1% of patients in the combined therapy. Slightly different values comes from reference [16] where the safety profile of zofenopril 30mg plus hydrochlorothiazide 12.5 mg did not differ significantly from that obtained with the corresponding mono-therapies (24% of patients with drug-related adverse events versus 20% with Z alone and 17% with HCTZ alone). Nevertheless, in such study it has been confirmed that the drug combination Z + HCTZ was significantly healthier for patients with the highest level of cardiovascular risk.

**ACE inhibitors and end-organ protection**

It has been shown that ACE inhibitors inhibit the formation of angiotensin II [operative molecule of the renin-angiotensin-aldosterone system (RAAS)] that has negative effect on endothelial, vascular and renal tissues [41]. Thus, activation of RAAS may have a beneficial effect in terms of end-organ protection, in addition to their effects on BP. Indeed, the SMILE (Survival of Myocardial Infarction Long-Term Evaluation) study has established the efficacy of Z in reducing the mortality due to Myocardial Infarction [43]. In addition, the combination therapy Z

<table>
<thead>
<tr>
<th>Table 4. Patients submitted to mono or combined therapy [parallel-group comparative study]; SBP: systolic blood pressure, DBP: diastolic blood pressure; *p&lt;0.05; **p&lt;0.01.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Studies</strong></td>
</tr>
<tr>
<td>Z. alone</td>
</tr>
<tr>
<td>Z + HCTZ</td>
</tr>
<tr>
<td>Z. alone</td>
</tr>
<tr>
<td>Z + HCTZ</td>
</tr>
</tbody>
</table>


Volume 3(4): 4-6
+ HCTZ has been proved able to normalise renal morphological and functional alterations, therefore reducing mortality, in hypertensive rats evaluated in a 8-week, placebo-controlled study [44]. Furthermore, and with respect to the metabolic parameters, no significant difference was observed between pre-treatment and treatment data and between Z as single treatment and the combination Z + HCTZ with respect to total cholesterol, HDL and LDL-cholesterol, triglycerides and glucose plasma concentrations [2,15]. However, the observed tendency of the combined therapy Z + HCTZ to reduce these parameters and in particular triglycerides and HLDL –cholesterol may support further the positive influence of such treatment within hypertension conditions.

Conclusions

In general, data from clinical trials evaluated in this and previous meta-analysis indicate that the combination therapy with Z + HCTZ 30/12.5 mg/day offers superior BP control in a larger amount of patients when compared to mono-therapy with Z alone 30 mg/day. In particular, studies in references [12-16] are the main source of blood pressure parameters with study in reference [13] being a randomised, homogeneous study showing response rate significantly increased (odd ratio 2.61 [1.55-4.39]) when HCTZ was added to treatment with Z alone. Accordingly, similar [slightly less pronounced] data come from studies in references [14] and [15]. Again, in the study from Malacco, et al. [16] combination treatment with Z plus HCTZ was associated with a significantly greater decrease in BP compared with Z mono-therapy with the difference between combined therapy and mono-therapy mostly marked for the group of patients at highest risk. Furthermore, data show that the combined therapy preserves the tolerability profile monitored in either Z or HCTZ mono-therapy thus favouring patient compliance.

In general, then it appears that the combined therapy Z + HCTZ has a safety profile although only the study in [15,45] is analysing lipid parameters with yet the evidence that no significant difference in total cholesterol, HDL and LDL-cholesterol, triglycerides and glucose plasma concentrations was detected following treatment with Z alone or Z + HCTZ versus pre-treatment values.

In conclusion then, the combined therapy Z + HCTZ appears to be effective for patients with BP insufficiently controlled by monotherapy. This conclusion is supported by the recent ZODIAC study showing the increased efficacy of 18 weeks of combined therapy Z + HCTZ on previous mono-therapy treated patients [46].

Long-term larger randomized clinical trials are yet needed to establish that the Z + HCTZ combination has the same cardiovascular and renal protective effects demonstrated by other ACE inhibitors.

References


Copyright: ©2017 Crespi F. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.